We are introducing a series over the next few months, for those interested in learning more about pharmaceutical pricing, reimbursement, and market access.
Topics will include:
- What is Market Access?
- What is a Payer?
- IRP – what it is and where to start
- Benefits of early dialogue with HTA
- What are Managed Entry Agreements?
- What is EMA HTA parallel consultation?
This months’ topic is ‘What is Market Access’ and covers how important having a robust market access strategy in place is for the successful launch of a product.
What is Market Access?
Market access is a broad term that is used to describe activities and processes that pharmaceutical and biotech companies undertake to secure a reimbursed price, which reflects the product’s value for the broadest possible patient population within the shortest feasible timeframe.
In order to deliver commercial success, a good market access strategy is required which identifies the product’s value from a payer […]